Henry Daniell
34Patents
9h-index
9Co-inventors
68Inventor score
Filing activity: Jul 20, 1994 → Feb 2, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5693507A | Genetic engineering of plant chloroplasts | Chemistry; Metallurgy | 194 | Expired |
| US6680426B2 | Genetic engineering of plant chloroplasts | Chemistry; Metallurgy | 86 | Expired |
| US7135620B2 | Genetic engineering of plant chloroplasts | Chemistry; Metallurgy | 76 | Expired |
| US5932479A | Genetic engineering of plant chloroplasts | Chemistry; Metallurgy | 64 | Expired |
| US6004782A | Hyperexpression of bioelastic polypeptides | Chemistry; Metallurgy | 36 | Expired |
| US7129391B1 | Universal chloroplast integration and expression vectors, transformed plants and products thereof | Emerging Cross-Sectional Technologies | 22 | Expired |
| US7294506B2 | Tobacco chloroplast transformation vectors comprising a multi-gene operon encoding a biopharmaceutical protein and a chaperonin | Emerging Cross-Sectional Technologies | 16 | Expired |
| US6642053B1 | Genetic engineering of plant chloroplasts | Chemistry; Metallurgy | 15 | Expired |
| US7803991B2 | Universal chloroplast integration and expression vectors, transformed plants and products thereof | Emerging Cross-Sectional Technologies | 10 | Active |
| US7354760B2 | Expression of protective antigens in transgenic chloroplasts | Emerging Cross-Sectional Technologies | 7 | Expired |
| US7795497B2 | Marker free transgenic plants: engineering the chloroplast genome without the use of antibiotic selection | Chemistry; Metallurgy | 5 | Expired |
| US10314893B2 | Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders | Emerging Cross-Sectional Technologies | 4 | Active |
| US7741536B2 | Expression of human serum albumin in plastids | Chemistry; Metallurgy | 3 | Active |
| US7767885B2 | Plastid genetic engineering via somatic embryogenesis | Chemistry; Metallurgy | 3 | Expired |
| US9605045B2 | Expression of the human IGF-1 in transgenic plastids | Human Necessities | 2 | Active |
| US10676751B2 | Production and use of plant degrading materials | Chemistry; Metallurgy | 2 | Active |
| US9657302B2 | Expression of human interferon in transgenic chloroplasts | Chemistry; Metallurgy | 2 | Active |
| US10233216B2 | Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients | Emerging Cross-Sectional Technologies | 1 | Active |
| US10556932B2 | Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients | Emerging Cross-Sectional Technologies | 0 | Active |
| US10655135B2 | Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes | General | 0 | Revoked |
| US10889825B2 | Compositions and methods thereof for down-regulation of genes following oral delivery of an RNAi molecule bioencapsulated within plant cells | Chemistry; Metallurgy | 0 | Active |
| US9885055B2 | Chloroplasts engineered to express pharmaceutical proteins | Chemistry; Metallurgy | 0 | Active |
| US10106585B2 | Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients | General | 0 | Revoked |
| US10865419B2 | Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes | Emerging Cross-Sectional Technologies | 0 | Active |
| US10806775B2 | Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertensions, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.